Clinical Trial

Genetic and Epigenetic Determinants of Response to Fluorouracil-based Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 15, 2022 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this laboratory research is to look for genetic and epigenetic markers that can predict which patients with stage III colorectal cancer will benefit from fluorouracil-based adjuvant chemotherapy.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2017-04-23; most recent amendment 2022-03-12.
Trial Details
NCT Number NCT03127111
Lead Sponsor Renmin Hospital of Wuhan University
Conditions Stage III Colorectal Cancer
Enrollment 300 participants
Start Date 2022-12-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2022-03-15